Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
Observer-blind Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Adjuvanted Quadrivalent Influenza Candidate Vaccines (GSK2584786A) in Children Aged 6 to 35 Months
Sponsor: GlaxoSmithKline
Terminated
The study was terminated for logistic reasons not related to safety or efficacy of the vaccine.
Other terminated trials from GlaxoSmithKline
Other Influenza trials with similar outcome
This PHASE2 trial investigates Influenza and Influenza Vaccines and is currently terminated or withdrawn. GlaxoSmithKline leads this study, which shows 12 recorded versions since 2010 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Terminated PHASE2
▶ Show 7 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
-
Aug 2018 — Nov 2020 [monthly]
Terminated PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Sep 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .